Abstract
Elexacaftor/tezacaftor/ivacaftor (ETI) has proven highly effective in people with cystic fibrosis (pwCF) carrying at least one F508del mutation. This prospective cohort study aims to better characterize the heterogeneity in responses to ETI and to identify patients who better respond to the treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Paper Title
Journal
Date
